Fasting Insulin vs. Fasting Glucose

Fasting insulin has become a favorite test in longevity circles, often pitched as an early warning that standard glucose tests miss. Fasting glucose is the familiar number on routine blood work. One is the band your friend just discovered; the other has been on the radio for decades. If you’re weighing fasting insulin vs. fasting glucose, the real difference is less about which is “better” and more about what each one can and can’t tell you. Humanic Blue lines the two up to see what each one actually offers.

Side by side, it breaks down like this. Fasting glucose measures blood sugar after at least 8 hours without food, and the American Diabetes Association uses it to diagnose prediabetes (100 to 125 mg/dL) and diabetes (126 mg/dL or higher). Fasting insulin measures the insulin concentration present at the same moment, but it has no agreed diagnostic cutoff for insulin resistance. In Whitehall II, a research estimate derived from fasting insulin and glucose changed years before diabetes diagnosis; that does not validate one fasting-insulin result as an early-warning test. A 2023 laboratory guideline from the American Diabetes Association (ADA) and American Association for Clinical Chemistry (AACC) says routine insulin testing is not recommended for most people with or at risk for diabetes or cardiovascular disease. For living longer and better, glucose-based criteria remain the clinical starting point; fasting insulin is mainly a research measure or a context-dependent test.

The two tests side by side

	Fasting glucose	Fasting insulin
What it measures	Blood sugar after 8+ hours without food	The concentration of insulin, the hormone that helps control blood sugar
Guideline role	Screening and diagnosis	Mostly research; selected clinical uses exist
Thresholds	Normal <100; prediabetes 100–125; diabetes ≥126 mg/dL	No agreed cutoffs
Comparability	Established diagnostic criteria	Results still differ among laboratory testing methods
What it adds	A recognized clinical category	Information about insulin levels, without a universal cutoff for insulin resistance

Why is fasting glucose the standard?

The ADA’s 2026 Standards of Care define fasting as no caloric intake for at least 8 hours. They list fasting plasma glucose below 100 mg/dL as below the prediabetes range, 100 to 125 mg/dL as prediabetes and 126 mg/dL or higher as diabetes. Without unequivocal hyperglycemia—unmistakably high blood sugar—an abnormal diagnostic result requires confirmation. HbA1c, a measure of average blood sugar over roughly three months, and the oral glucose tolerance test are also accepted screening and diagnostic options.

Fasting glucose has a weakness: in the ARIC study, it didn’t predict heart disease or death once HbA1c was taken into account, as covered in HbA1c and Healthy Aging.

Is fasting insulin an earlier signal?

When tissues respond less well to insulin, the pancreas may initially release more to maintain glucose. That physiology helps explain why researchers study insulin alongside glucose. It does not mean every person with a particular fasting-insulin value has insulin resistance; how much insulin the pancreas releases, how quickly the body removes it, fasting conditions and the laboratory method all affect the result.

The Whitehall II study described a group-level timeline. In a 2009 analysis in The Lancet, researchers followed British civil servants for about a decade. Some developed diabetes during that time. Among those who developed it:

• Insulin sensitivity, how well tissues respond to insulin, fell steeply over the 5 years before diagnosis.
• Fasting glucose rose slowly, then climbed steeply from about 3 years before diagnosis.
• Beta-cell output, insulin release from the pancreas’s insulin-producing cells, rose briefly between 4 and 3 years before diagnosis, then fell.

The patterns in people who later developed diabetes began to differ from those in people who did not, three to six years before diagnosis. Insulin sensitivity was not measured by fasting insulin alone; it was estimated with HOMA, which combines fasting insulin and glucose. The study group was mostly men employed in the British civil service, which limits how well its findings apply to other people.

What would turn an early physiological signal into a validated screening tool?

HOMA-IR: combining the two

HOMA, short for homeostasis model assessment, combines fasting insulin and glucose to estimate how the body regulates blood sugar. HOMA-IR is its estimate of insulin resistance: how poorly tissues respond to insulin. The model was introduced in a 1985 methods paper in Diabetologia. In the small validation samples, its insulin-resistance estimate tracked a reference laboratory test called a glucose clamp, which measures the body’s response to insulin under controlled conditions. But repeat HOMA estimates varied substantially. Because HOMA depends on insulin measurement, it also inherits assay and fasting-condition differences. A research correlation does not create one universal clinical cutoff.

What’s the catch with fasting insulin tests?

This is where the proposed early signal meets a very ordinary problem: the rulers do not fully match. An ADA workgroup reported in 2007 that commercial insulin-testing methods could give substantially different results. More recent evidence shows the issue has not disappeared: a 2022 comparison of seven insulin assay kits found substantial differences and problems matching results to shared reference standards and converting between units consistently.

The 2023 ADA/AACC laboratory guideline concludes that routine testing of insulin or its precursor, proinsulin, is not recommended for most people with diabetes or at risk for diabetes or cardiovascular disease; it describes these assays as primarily useful for research and calls for standardization. That is stronger guidance than simply saying the test needs a better reference range.

How would differences between insulin assays affect comparisons of HOMA-IR results?